Summary
This is a first-in-human open-label Phase 1/2a study to evaluate the safety, tolerability,
pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-00610 given by
intravenous infusion in patients with advanced solid malignancies who have progressed on all
available standard therapies